Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors
Abstract Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions
through an anchored transmembrane molecule and a soluble circulating protein. Both …
through an anchored transmembrane molecule and a soluble circulating protein. Both …
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Introduction Obesity is recognized as a major healthcare challenge. Following years of slow
progress in discovery of safe, effective therapies for weight management, recent approval of …
progress in discovery of safe, effective therapies for weight management, recent approval of …
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker - Diabetes care, 2003 - diabetesjournals.org
OBJECTIVE—To examine the mechanisms of action, therapeutic potential, and challenges
inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the …
inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the …
Incretins, insulin secretion and type 2 diabetes mellitus
When glucose is taken orally, insulin secretion is stimulated much more than it is when
glucose is infused intravenously so as to result in similar glucose concentrations. This effect …
glucose is infused intravenously so as to result in similar glucose concentrations. This effect …
[PDF][PDF] Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action
DJ Drucker - Diabetes care, 2007 - glucagon.com
Dipeptidyl peptidase (DPP)-4 is a complex enzyme that exists as a membrane-anchored cell
surface peptidase that transmits intracellular signals via a short intracellular tail and as a …
surface peptidase that transmits intracellular signals via a short intracellular tail and as a …
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
NA Thornberry, B Gallwitz - Best practice & research Clinical endocrinology …, 2009 - Elsevier
Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins, glucagon-
like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). The first …
like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). The first …
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control …
Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important
factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential …
factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential …
Reappraisal of GIP pharmacology for metabolic diseases
Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type
2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body …
2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body …
DPP-4 inhibition and the path to clinical proof
B Ahrén - Frontiers in endocrinology, 2019 - frontiersin.org
In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates
the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent …
the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent …
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
RE Pratley, A Salsali - Current medical research and opinion, 2007 - Taylor & Francis
ABSTRACT Background: Glucagon-like peptide-1 (GLP‑1) and glucose-dependent
insulinotropic polypeptide (GIP) are hormones secreted by the enteroendocrine cells of the …
insulinotropic polypeptide (GIP) are hormones secreted by the enteroendocrine cells of the …